



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Jo Caers

✉ Jo.Caers@chuliege.be

RECEIVED 03 November 2025

REVISED 04 November 2025

ACCEPTED 14 November 2025

PUBLISHED 02 December 2025

CITATION

Jassin M, Block A, Désiront L, Vrancken L, Grégoire C, Baron F, Ehx G, Nguyen TT and Caers J (2025) Correction: From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors. *Front. Immunol.* 16:1738434. doi: 10.3389/fimmu.2025.1738434

COPYRIGHT

© 2025 Jassin, Block, Désiront, Vrancken, Grégoire, Baron, Ehx, Nguyen and Caers. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors

Mégane Jassin¹, Alix Block^{1,2}, Laury Désiront¹, Louise Vrancken^{1,2}, Céline Grégoire², Frédéric Baron^{1,2}, Grégory Ehx^{1,3}, Thi Tham Nguyen¹ and Jo Caers^{1,2*}

¹Laboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (IGIA) Institute, University of Liege, Liege, Belgium, ²Department of Hematology, University Hospital of Liege, Liege, Belgium, ³Walloon Excellence in Life Sciences and Biotechnology (WELBIO) Department, Walloon Excellence in Life Research Institute, Wavre, Belgium

KEYWORDS

car-t, chimeric antigen receptor T cells, solid tumor, 3D culture, tumor microenvironment, spheroid, organoid, immunotherapy

A Correction on

From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors

By Jassin M, Block A, Désiront L, Vrancken L, Grégoire C, Baron F, Ehx G, Nguyen TT and Caers J (2025) *Front. Immunol.* 16:1626369. doi: 10.3389/fimmu.2025.1626369

There was a mistake in the caption of **Figure 6** as published. Figure incomplete (missing words, empty square without “collagen matrix, tumor organoid, hydrogel matrix, biopsy derived cells”). The corrected caption of **Figure 6** appears below.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 6

Schematic representation of using matrix coupled with microfluidic, organ-on-chip and bioprinting. Microfluidic device is composed of different channels, one to culture the spheroid or organoid with CAR-T cells while other channels can bring oxygen, nutrients, chemotaxis molecules or growth factors or can mimic blood vessels. Channels can be coupled with filters to remove debris and dead cells. This figure was generated on Biorender.